Zacks: Brokerages Anticipate Aclaris Therapeutics Inc (ACRS) to Announce -$1.25 EPS

Wall Street analysts expect Aclaris Therapeutics Inc (NASDAQ:ACRS) to report earnings per share of ($1.25) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aclaris Therapeutics’ earnings, with the highest EPS estimate coming in at ($1.24) and the lowest estimate coming in at ($1.26). Aclaris Therapeutics reported earnings of ($0.63) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 98.4%. The business is expected to announce its next earnings results on Tuesday, November 6th.

On average, analysts expect that Aclaris Therapeutics will report full-year earnings of ($4.54) per share for the current year, with EPS estimates ranging from ($4.55) to ($4.53). For the next financial year, analysts expect that the business will report earnings of ($3.93) per share, with EPS estimates ranging from ($4.05) to ($3.87). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Aclaris Therapeutics.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.04. Aclaris Therapeutics had a negative net margin of 1,584.99% and a negative return on equity of 49.45%. The company had revenue of $3.68 million during the quarter, compared to the consensus estimate of $2.76 million.

A number of equities analysts recently commented on ACRS shares. Cantor Fitzgerald set a $50.00 target price on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a research report on Monday, July 9th. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 24th. Finally, BidaskClub cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Aclaris Therapeutics presently has an average rating of “Buy” and an average price target of $41.60.

In other Aclaris Therapeutics news, Director Anand Mehra bought 372,093 shares of the firm’s stock in a transaction that occurred on Monday, October 22nd. The shares were bought at an average price of $10.75 per share, for a total transaction of $3,999,999.75. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Stephen A. Tullman bought 6,250 shares of the firm’s stock in a transaction that occurred on Wednesday, August 15th. The stock was acquired at an average price of $15.97 per share, for a total transaction of $99,812.50. Following the transaction, the director now owns 163,757 shares in the company, valued at $2,615,199.29. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 392,043 shares of company stock worth $4,298,212. 17.00% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. A.R.T. Advisors LLC raised its position in Aclaris Therapeutics by 4.8% in the 1st quarter. A.R.T. Advisors LLC now owns 57,300 shares of the biotechnology company’s stock worth $1,003,000 after purchasing an additional 2,600 shares during the period. MetLife Investment Advisors LLC increased its position in shares of Aclaris Therapeutics by 32.7% in the second quarter. MetLife Investment Advisors LLC now owns 13,157 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 3,244 shares during the period. Russell Investments Group Ltd. increased its position in shares of Aclaris Therapeutics by 7.4% in the first quarter. Russell Investments Group Ltd. now owns 49,450 shares of the biotechnology company’s stock valued at $867,000 after acquiring an additional 3,421 shares during the period. Alps Advisors Inc. increased its position in shares of Aclaris Therapeutics by 8.4% in the second quarter. Alps Advisors Inc. now owns 44,847 shares of the biotechnology company’s stock valued at $896,000 after acquiring an additional 3,478 shares during the period. Finally, Metropolitan Life Insurance Co. NY increased its position in shares of Aclaris Therapeutics by 48.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 11,056 shares of the biotechnology company’s stock valued at $221,000 after acquiring an additional 3,589 shares during the period. Institutional investors own 99.74% of the company’s stock.

Shares of NASDAQ:ACRS opened at $11.90 on Tuesday. The firm has a market capitalization of $374.25 million, a P/E ratio of -4.76 and a beta of 1.22. Aclaris Therapeutics has a 52 week low of $11.00 and a 52 week high of $26.25.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Further Reading: Relative Strength Index

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply